| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10406199 | AZURITY | Lisinopril formulations |
Nov, 2035
(11 years from now) | |
| US10039800 | AZURITY | Lisinopril formulations |
Nov, 2035
(11 years from now) | |
| US9616096 | AZURITY | Lisinopril formulations |
Nov, 2035
(11 years from now) | |
| US10265370 | AZURITY | Lisinopril formulations |
Nov, 2035
(11 years from now) | |
| US9463183 | AZURITY | Lisinopril formulations |
Nov, 2035
(11 years from now) | |
| US11179434 | AZURITY | Lisinopril formulations |
Nov, 2035
(11 years from now) | |
| US9814751 | AZURITY | Lisinopril formulations |
Nov, 2035
(11 years from now) | |
| US10940177 | AZURITY | Lisinopril formulations |
Nov, 2035
(11 years from now) | |
| US11771733 | AZURITY | Lisinopril formulations |
Nov, 2035
(11 years from now) | |
Qbrelis is owned by Azurity.
Qbrelis contains Lisinopril.
Qbrelis has a total of 9 drug patents out of which 0 drug patents have expired.
Qbrelis was authorised for market use on 29 July, 2016.
Qbrelis is available in solution;oral dosage forms.
Qbrelis can be used as acute myocardial infarction, method of treating hypertension, method of treatment of heart failure.
The generics of Qbrelis are possible to be released after 06 November, 2035.
Drugs and Companies using LISINOPRIL ingredient
Market Authorisation Date: 29 July, 2016
Treatment: Acute myocardial infarction; Method of treating hypertension; Method of treatment of heart failure
Dosage: SOLUTION;ORAL
QBRELIS family patents
